Annexon (NASDAQ:ANNX) used its Investor Day presentation to outline the scientific rationale and clinical progress for ...
Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside ...
Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A .
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous ...
(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
India, March 13 -- Allergic rhinitis, often called hay fever, affects hundreds of millions of people worldwide and commonly ...
Ketogenic diet therapies, including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment, have ...
This unexpected Pennsylvania park features a beautiful Japanese house and garden, perfect for quiet walks and soaking in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results